Johnson & Johnson Q4 2025 Earnings Analysis

**Beta Finch Podcast Script: Johnson & Johnson Q4 2025**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and joining me as always is my co-host Jordan. Today we're dissecting Johnson & Johnson's Q4 2025 earnings call, and wow - what a way to cap off the year.Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Thanks Alex, and yeah, JNJ really delivered here. They're calling 2025 a "catapult year" - and the numbers back that up. Let's start with the headline figures because they're impressive across the board.ALEX: Absolutely. Fourth quarter operational sales growth came in at 7.1%, which is solid, but the full-year picture is even better. They hit $94.2 billion in total revenue for 2025 with 5.3% operational growth. But here's the kicker, Jordan - they're guiding for $100 billion at the midpoint for 2026. That's a massive psychological milestone for any healthcare company.JORDAN: Right, and what's fascinating is how they're positioning this growth. CEO Joaquin Duato kept emphasizing their "28 billion-dollar products" - that's an incredible diversification of revenue streams. No other healthcare company has that kind of breadth. They're not relying on one or two blockbusters like some of their competitors.ALEX: Let's break down the two main segments. On the Innovative Medicine side, they posted 5.3% operational growth for the year, crossing $60 billion in pharma sales for the first time. The star performer here continues to be DARZALEX in multiple myeloma - $14 billion in annual sales with 22% growth. That's just staggering for a drug of that size.JORDAN: And they're not stopping there. The multiple myeloma franchise is becoming a juggernaut. They mentioned being the number one company in that space, with 80% of patients treated with at least one of their four medicines. Plus, CARVICTI, their CAR-T therapy, is showing strong momentum with over 10,000 patients treated across 14 markets.ALEX: The immunology story is equally compelling. Tremfya hit $5 billion in sales and grew 65% in Q4 - that's not a typo, sixty-five percent! They're confident it'll exceed $10 billion in peak sales, especially as it continues taking share in inflammatory bowel disease where STELARA used to dominate.JORDAN: Speaking of STELARA, that's the elephant in the room that's actually becoming less relevant. STELARA declined 48.6% due to biosimilar competition, but here's what's remarkable - JNJ grew double digits for the full year excluding STELARA. They've successfully navigated that cliff, which was a major investor concern.ALEX: Now let's talk MedTech. 5.4% operational growth for the year with some really strong pockets. Cardiovascular was the standout with 15% operational growth, reaching $9 billion. The Abiomed and Shockwave acquisitions are clearly paying dividends here.JORDAN: What caught my attention was their robotics ambition. They just submitted their Ottava robotic surgery system for FDA approval via a de novo pathway - meaning there's no predicate device to compare it against. That suggests they truly believe they have something differentiated in a space dominated by Intuitive Surgical.ALEX: The guidance for 2026 is aggressive but achievable based on their pipeline momentum. 5.7% to 6.7% operational sales growth, with that $100 billion midpoint I mentioned. Adjusted EPS growth of 5.5% at the midpoint, which factors in about $500 million in medtech tariffs - significantly higher than 2025.JORDAN: I want to highlight something CFO Joe Wolk said about margins. They're expecting at least 50 basis points of adjusted operating margin improvement despite those tariff headwinds and increased investment inThis episode includes AI-generated content.